Replies to post #255337 on Biotech Values

[mouton29]

For Paxlovid, the label is similarly "restricted" to adults who are at high risk for progression to severe COVID-19. The label lists 12 specific conditions or factors that place a patient at high risk and then proceeds add a catch-all giving the “healthcare provider” even more discretion:

Other medical conditions or factors (e.g., race or ethnicity) may also place individual patients
at high risk for progression to severe COVID-19 and are not limited to the medical conditions
or factors listed above. Healthcare providers should consider the benefit-risk for an individual
patient

.


https://labeling.pfizer.com/ShowLabeling.aspx?id=19730#page2

In contrast the Nuvaxovid label provides no definition of high risk.  

https://www.fda.gov/media/186544/download?attachment

I think in practice, the prescribing doctor makes the decision when he or she decides to write the prescription; I can't imagine a pharmacist refusing to fill a prescription.

[vinmantoo]

The amusing things about RFK is he’s virtually certain to accomplish nothing useful at all. Very much like all the TechBros in biotech (who often love RFK).

The best scenario is RFK Jr. would accomplish nothing. The reality is that he is already damaging US healthcare and science.